Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.
A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.
Authors
- Jo Anne Welsch
- Lionel Martellet (ORCID: https://orcid.org/0000-0002-2454-4614)
- Milagritos Tapia
- Ed Clarke (ORCID: https://orcid.org/0000-0002-7785-0340)
- Dhananjay Kapse
- Mark R. Alderson (ORCID: https://orcid.org/0000-0002-0697-6149)
- Magnus Ochoge
- Fatoumata DIALLO
- Niranjan Bhat (ORCID: https://orcid.org/0000-0001-9249-5028)
- Yuxiao Tang
- Prasad S. Kulkarni (ORCID: https://orcid.org/0000-0003-3625-9236)
- Samba Sow
- Fadima Haidara
- Ama Umesi
- F Marc LaForce
- Nancy Hosken
Institutions
- University of Maryland, Baltimore (US)
- Program for Appropriate Technology in Health (US)
- Serum Institute of India (India) (IN)
- Centre Pour le Développement des Vaccins-Mali (ML)
- London School of Hygiene & Tropical Medicine (GB)
- MRC Unit the Gambia (GM)
- Medical Research Council (GB)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/cid/ciag693
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00